Proteomics of *Staphylococcus aureus* biofilm matrix in a rat model of orthopedic implant-associated infection

Mei G. Lei*, Ravi Kr. Gupta*, Chia Y. Lee*

Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

* These authors contributed equally to this work.

**clee2@uams.edu**

Abstract

The matrix proteins of *Staphylococcus aureus* biofilm have not been well defined. Previous efforts to identify these proteins were performed using in vitro systems. Here we use a proteomic approach to identify biofilm matrix proteins directly from infected bone implants using a rat model of orthopedic implant-associated *S. aureus* infection. Despite heavy presence of host proteins, a total of 28 and 105 *S. aureus* proteins were identified during acute infection and chronic infection, respectively. Our results show that biofilm matrix contains mostly intracellular cytoplasmic proteins and, to a much less extent, extracellular and cell surface-associated proteins. Significantly, leukocidins were identified in the biofilm matrix during chronic infection, suggesting *S. aureus* is actively attacking the host immune system even though they are protected within the biofilm. The presence of two surface-associated proteins, Ebh and SasF, in the infected bone tissue during acute infection was confirmed by immunohistochemistry. In addition, a large number of host proteins were found differentially expressed in response to *S. aureus* biofilm formed on bone implants.

Introduction

*Staphylococcus aureus* can cause a range of infections. Treatment for *S. aureus* infections is largely limited to conventional antibiotic therapy but failures are common due to emergence of antibiotic resistance strains as well as intrinsic antibiotic resistance attributed to biofilm formation. Biofilm is composed of multiple layers of bacteria encased and interconnected in an extracellular matrix that forms a complex three-dimensional structure, which provides protection against host defenses and limits the therapeutic efficacy of all currently available antibiotics [1, 2].

Biofilm formation is a complicated process that collectively includes three distinct phases—attachment, accumulation, and dispersal [2, 3]. Polysaccharide intracellular adhesion (PIA) is a major component in the biofilm matrix [4]. However, many *S. aureus* strains have been shown to form a PIA-independent biofilm composed of proteins and/or bacterial extracellular DNA (eDNA) [5–7]. These studies indicate that *S. aureus* biofilm matrix contains a large
number of proteins but most of them have not yet been identified [6, 7]. However, these studies were all conducted by culturing bacterial cells under in vitro conditions and it is unclear whether the factors identified by in vitro studies reflect those present in biofilms formed in vivo. A recent study [8] revealed that only 26 of the more than 100 matrix proteins present in an in vitro S. aureus biofilm were recognized by antibodies from rabbits with experimental osteomyelitis, suggesting that matrix composition of biofilms formed in vitro is likely to be very different from biofilms formed in vivo. In this study, we address this issue by identifying matrix protein components in biofilms formed under in vivo conditions using a clinically relevant animal model of bone implant infection in rats. We identified a number of S. aureus proteins associated with biofilm matrix from bone implants during acute and chronic phases of infections. These proteins include secreted, surface proteins, but mostly intracellular proteins. Our results further indicate that direct identification of biofilm matrix proteins from infected tissues is feasible under our experimental condition.

Results
Development of a rat model of orthopedic-implant infection
To identify biofilm matrix proteins in vivo, we first developed a clinically relevant biofilm model to directly identify S. aureus biofilm matrix proteins in infected tissues. Recently, a post-arthroplasty S. aureus joint infection mouse model has been reported [9, 10]. We followed this model closely with two minor modifications. First, we used large rats based on the rationale that large rats would allow for larger implants to be placed in the femur than in mice, which would accommodate more bacteria to attach the implants thereby producing more biofilm materials. Second, we also employed stainless steel tubing in place of thin wire to increase biofilm volume by increasing the implant surface area and providing additional space within the implant. The groove at the distal end of the femur was exposed by skin incision and laterally displacing quadriceps-patellar complex. An opening was made at the center of the lower end of the femur and a piece of stainless metal tubing was inserted into the femoral canal. In pilot studies, we found tubing with 15G in size and 1-cm in length could be readily inserted into femoral canal. Tubing that is longer or larger in size was difficult to insert. In this model, we found presoaking the implants with 1x10⁴ CFU/ml for 30–60 min before placing into the femoral canal followed by inoculation of 50 CFUs of bacteria into the implant lumen would lead to visually marked swelling at day 6 post-infection with a bacterial load of 3x10⁶ to 2x10⁸ CFUs per implant. The same inoculum also led to low levels of bacterial load of 7x10² to 2.3x10⁴ CFUs per implant at day 45. It should be noted here that presoaking implants in 1x10⁹ CFUs or inoculating higher inoculum (250 or 1,500 CFUs) into the implant lumen did not increase the bacterial load at day 6 or day 45 post-infection. The bacterial load and swelling at day 6 and day 45 post-infection were similar to the conditions defined as acute and chronic infection, respectively, in the post-arthroplasty S. aureus joint infection mouse model [9,10]. Thus, in this study, the time points at day 6 and 45 post-infection were used to study biofilm matrix proteins representing acute and chronic infection, respectively.

Identification of biofilm matrix proteins from infected implants during an acute infection
To identify biofilm matrix proteins from an acute infection, we carried out the rat model described above. Two independent experiments were performed in which the implants were infected with S. aureus UAMS-1 or PBS. UAMS-1 was chosen because it is a clinical isolate from a patient with osteomyelitis [11]. All rats were able to walk on the surgical leg after day 1
post-infection. From day 2 to 6, only the control rats were able to walk normally on the surgical leg. All animals were sacrificed at day 6 post-infection at which time all infected animals had swollen joints while the control animals had no swelling. The implants were removed to harvest biofilm and determine bacterial load. In each experiment, the source of biofilm was pooled from implants of two infected rats with bacterial counts ranging from $7 \times 10^6$ to $2.4 \times 10^7$ CFUs/implant. Protein fractions associated with the implants were collected for either exoprotein proteome (secretome) after sonication or SDS-extracted surface proteome (surfactome) analysis. It should be noted here that extraction by 4% SDS solution has been shown to release proteins that are associated with cell surface but not covalently anchored on the cell wall [12, 13]. The proteins were separated by SDS-PAGE and subjected to in-gel trypsin digestion followed by liquid chromatography-tandem MS (GeLC-MS/MS) analysis. Proteins were identified by Mascot search against UAMS-1 protein database [11, 14] using relatively stringent criteria of 99% protein threshold and a minimum of 2 peptides per protein sequence with 1% false detection rate. We found the vast majority of the proteins identified were rat proteins as expected and most bacterial proteins identified were low in abundance. We therefore considered positive identification of any protein that was present in both two independent experiments. We identified 11 and 17 UAMS-1-specific proteins from the secretome and surfactome, respectively (Tables 1 and 2), of which six proteins were found common to both proteomes.

Only two surface or secreted proteins were identified in the secretome—Ebh, a very large extracellular matrix binding protein, which is surface associated and able to bind human fibronectin [15, 16], and a putative exported protein (QV15_04425). In the surfactome, IsdA, a surface anchored protein with LPXTG motif [17], was the only surface or secreted protein identified. In contrast, the majority of the proteins identified in both proteomes are cytoplasmic proteins or enzymes involved in cellular process and metabolism. Oct (ornithine carbamoyltransferase) and Idh2 (Lactate dehydrogenase) were the most abundant proteins in the

Table 1. Proteins identified in secretome of acute phase infection.

| ORFa QV15_ | gene | Identified Proteins | IDb | Mass (kDa) | Normalized count (expt 1/2)c | P value |
|------------|------|---------------------|-----|-----------|-------------------------------|---------|
| 05465*     | otc  | ornithine carbamoyltransferase | KHF80801.1 | 38 | 7.6/28.6 | 0/0 | 0.114 |
| 13410*     | ldh2 | lactate dehydrogenase | KHF79648.1 | 34 | 21.8/5.3 | 0/0 | 0.121 |
| 05815      | fth  | signal recognition particle | KHF80870.1 | 51 | 9.5/5.3 | 0/0 | 0.036 |
| 04425      |    a | hypothetical protein [putative exported protein] | KHF80604.1 | 16 | 7.6/4.2 | 0/0 | 0.036 |
| 07005      | ebh  | matrix-binding protein | KHF81094.1 | 1135 | 5.7/4.2 | 0/0 | 0.010 |
| 13620*     | arcB | ornithine carbamoyltransferase | KHF79689.1 | 38 | 1.9/7.4 | 0/0 | 0.117 |
| 02780      | adhA | ethanol-active dehydrogenase/ acetaldheyde-active reductase | KHF80299.1 | 36 | 1.9/1.1 | 0/0 | 0.036 |
| 05335      | trxA | thioredoxin | KHF80778.1 | 11 | 1.9/1.1 | 0/0 | 0.036 |
| 03870      | eno  | enolase | KHF80499.1 | 47 | 1.9/1.1 | 0/0 | 0.036 |
| 04315*     | glpQ | glycerophosphodiester phosphodiesterase | KHF80583.1 | 35 | 0.99/2.1 | 0/0 | 0.060 |
| 08415      | uspA | universal stress protein UspA | KHF81365.1 | 18 | 0.99/1.1 | 0/0 | 0.002 |

aORF numbers are based on strain UAMS-1. ORF numbers with an asterisk (*) indicate proteins with a P value of >0.05. ORF numbers that are underlined indicate proteins also found in chronic secretome.
bThe ID number is the Uniprot accession number.
cTwo biological replicates were used to identify matrix proteins. The spectral counts were normalized based on total counts.
d—a gene name has not yet been assigned.

https://doi.org/10.1371/journal.pone.0187981.t001
secretome representing about half of all spectral counts, whereas PflB (formate acetyltransferase), which is involved in fermentation pathway, was the most abundant one representing almost half amount of the total spectral counts in the surfactome. Among these cytoplasmic proteins, TxrA (thioredoxin) and UspA (universal stress protein A), which were found in both proteomes, are potentially involved in virulence. TrxA is involved in redox homeostasis and removal of reactive oxygen species [18]. UspA has been shown to respond to stresses in other bacteria [19, 20] and to contribute to virulence in Salmonella [21]. The role of TxrA and UspA in S. aureus has not been studied. The presence of cytoplasmic proteins in the biofilm matrix is interesting but not surprising as these proteins have been reported to locate extracellularly in a variety of bacteria under different conditions including biofilms (reviewed in [22, 23]). A recent study also showed an increase in cytoplasmic proteins on the surface of S. aureus during biofilm formation in vitro [24].

Table 2. Proteins identified in surfactome of acute phase infection.

| ORF* QV15_ | gene   | Identified Proteins                               | IDb | Mass (kDa) | Normalized count (expt 1/2)c | P value expt control |
|-----------|--------|---------------------------------------------------|-----|------------|------------------------------|---------------------|
| 00825     | pflB   | formate acetyltransferase                         | KHF79941.1 | 85       | 120.0/118.0                | 0/0                | <0.001              |
| 10795     | atpA   | ATP F0F1 synthase subunit alpha                   | KHF79165.1 | 55       | 26.7/20.9                 | 0/0                | 0.007               |
| 02495     | tuf    | elongation factor Tu                              | KHF80244.1 | 43       | 20.0/17.7                 | 0/0                | 0.002               |
| 00485     | adhE   | acetaldehyde dehydrogenase                        | KHF79877.1 | 95       | 14.7/11.2                 | 0/0                | 0.009               |
| 08415     | uspA   | universal stress protein UspA                     | KHF81365.1 | 18       | 10.7/12.0                 | 0/0                | 0.002               |
| 02780     | adhA   | ethanol-active dehydrogenase/ acetaldehyde-active reductase | KHF80299.1 | 36       | 8.0/13.6                 | 0/0                | 0.031               |
| 05465*    | otc    | ornithine carbamoyltransferase                    | KHF80801.1 | 38       | 2.7/14.4                 | 0/0                | 0.142               |
| 13410*    | idh2   | lactate dehydrogenase                             | KHF79648.1 | 34       | 17.3/4.0                  | 0/0                | 0.125               |
| 13610*    | arcC2  | carbamate kinase                                  | KHF79687.1 | 34       | 1.3/7.2                  | 0/0                | 0.142               |
| 05470*    | arcC1  | carbamate kinase                                  | KHF80802.1 | 34       | 1.3/6.4                  | 0/0                | 0.133               |
| 07020*    | tdcB   | threonine dehydratase                             | KHF81097.1 | 37       | 2.7/5.6                  | 0/0                | 0.053               |
| 05335     | trxA   | thioredoxin                                       | KHF80778.1 | 11       | 5.3/3.2                  | 0/0                | 0.028               |
| 11465     | rpsE   | 30S ribosomal protein S5                          | KHF79285.1 | 18       | 2.7/2.4                  | 0/0                | 0.001               |
| 07025     | ald2   | alanine dehydrogenase                             | KHF81098.1 | 40       | 2.7/1.6                  | 0/0                | 0.028               |
| 06820     | cspA   | cold-shock protein                                | KHF81061.1 | 7        | 4.0/3.2                  | 0/0                | 0.006               |
| 03870     | eno    | enolase                                           | KHF80499.1 | 47       | 1.3/1.6                  | 0/0                | 0.004               |
| 05255*    | isdA   | heme transporter IsdA                             | KHF80763.1 | 39       | 2.7/0.8                  | 0/0                | 0.102               |

*ORF numbers are based on strain UAMS-1. ORF numbers with an asterisk (*) indicate proteins with a P value of >0.05. ORF numbers that are underlined indicate proteins also found in chronic surfactome.

The ID number is the Uniprot accession number.

Two biological replicates were used to identify matrix proteins. The spectral counts were normalized based on total counts.

https://doi.org/10.1371/journal.pone.0187981.t002

Identification of biofilm matrix proteins from infected implants during a chronic infection

To identify biofilm matrix proteins during a chronic infection, the infected rats were sacrificed at day 45. At the time of sacrifice, the S. aureus infected animals were slightly limping while walking. The joints were also less visually swelling compared to those of the acute phase. Because of low bacterial burdens, we pooled the proteins from 4 rats in each of the two experiments. The bacterial counts from individual implants were 7.0x10^2–1.6x10^4 CFUs.
and $2.4 \times 10^3 - 2.3 \times 10^4$ CFUs for the two independent experiments, respectively. We identified 33 and 72 proteins from the secretome and surfactome, respectively, in which 22 were in both fractions (Tables 3 and 4). Similar to the proteins identified during the acute phase infection, most of the proteins are cytoplasmic in nature. Furthermore, 8 of the 11 proteins

Table 3. Proteins identified in secretome of chronic phase infection.

| ORF\(^a\) QV15\_ | gene | Identified Proteins | ID\(^b\) | Mass (kDa) | Normalized count (expt 1/2)\(^c\) | P value  \\
|-----------------|------|----------------------|--------|------------|-----------------|---------|
| 05465 otc      | ornithine carbamoyltransferase | KHF80801.1 | 38 | 96.0/86.5 | 0/0 | 0.001 |
| 0025 pflB      | formate acetyltransferase | KHF79941.1 | 85 | 21.35/15.6 | 0/0 | 0.011 |
| 02920 mntA     | manganese ABC transporter substrate-binding protein | KHF80325.1 | 35 | 15.4/18.2 | 0/0 | 0.003 |
| 10785\(^*\) atpD | ATP F0F1 synthase subunit beta | KHF79163.1 | 51 | 23.7/11.2 | 0/0 | 0.054 |
| 01655 ahpC     | alkyl hydroperoxide reductase | KHF80100.1 | 21 | 13.0/13.0 | 0/0 | <0.001 |
| 10225 lukA     | Leukocidin toxin subunit A | KHF79059.1 | 41 | 8.3/11.2 | 0/0 | 0.011 |
| 07765 dnaK     | molecular chaperone DnaK | KHF81241.1 | 66 | 11.9/7.8 | 0/0 | 0.020 |
| 03870 eno      | enolase | KHF80499.1 | 47 | 8.3/9.5 | 0/0 | 0.002 |
| 10220 lukB     | Leukocidin toxin subunit B | KHF79058.1 | 39 | 7.1/8.6 | 0/0 | 0.005 |
| 13410 ldh2     | lactate dehydrogenase | KHF79648.1 | 34 | 7.1/8.6 | 0/0 | 0.005 |
| 13685\(^*\) sasF | adhesin | KHF79021.1 | 70 | 2.4/9.5 | 0/0 | 0.119 |
| 06125\(^*\) mutL | DNA mismatch repair protein MutL | KHF80932.1 | 77 | 24/8.6 | 0/0 | 0.011 |
| 05255 isdA     | heme transporter IsdA | KHF80763.1 | 39 | 4.7/6.1 | 0/0 | 0.007 |
| 02780 adhA     | ethanol-active dehydrogenase/ acetaldehyde-active reductase | KHF80299.1 | 36 | 4.7/5.2 | 0/0 | 0.001 |
| 04845 atl      | mannosyl-glycoprotein endo-beta-N-acetylg glucosamidase (bifunctional autolysin) | KHF80684.1 | 138 | 4.7/5.2 | 0/0 | 0.001 |
| 07005 ebh      | matrix-binding protein | KHF81094.1 | 1135 | 2.4/6.1 | 0/0 | 0.075 |
| 07020 tdcB     | threonine dehydratase | KHF81097.1 | 37 | 3.6/5.2 | 0/0 | 0.017 |
| 12485\(^*\) hlgA | gamma-hemolysin subunit A | KHF79477.1 | 35 | 2.4/6.1 | 0/0 | 0.075 |
| 05335 trxA     | thioredoxin | KHF80778.1 | 11 | 3.6/4.3 | 0/0 | 0.005 |
| 12495 hlgB     | gamma-hemolysin subunit B | KHF79479.1 | 31 | 4.7/2.6 | 0/0 | 0.039 |
| 04315 gipQ     | glycerophosphodiester phosphodiesterase | KHF80583.1 | 35 | 3.6/3.5 | 0/0 | <0.001 |
| 11185\(^*\)   | iron citrate ABC transporter substrate-binding protein | KHF79234.1 | 37 | 3.6/3.5 | 0/0 | <0.001 |
| 03850 gap1     | glyceraldehyde-3-phosphate dehydrogenase | KHF80495.1 | 36 | 3.6/2.6 | 0/0 | 0.012 |
| 04330\(^*\) pgi | glucose-6-phosphate isomerase | KHF80586.1 | 50 | 3.6/0.9 | 0/0 | 0.121 |
| 02495 tuf      | elongation factor Tu | KHF80244.1 | 43 | 2.4/1.7 | 0/0 | 0.012 |
| 11605\(^*\)   | multidrug transporter | KHF79313.1 | 115 | 1.2/2.6 | 0/0 | 0.058 |
| 00485\(^*\) adhE | acetaldehyde dehydrogenase | KHF79877.1 | 95 | 1.2/2.6 | 0/0 | 0.058 |
| 08415\(^*\) uspA | universal stress protein UspA | KHF81365.1 | 18 | 1.2/2.6 | 0/0 | 0.058 |
| 08265\(^*\) thrS | threonyl-tRNA synthase | KHF81336.1 | 74 | 2.4/0.9 | 0/0 | 0.088 |
| 05080 pdhD     | dihydrolipoamide dehydrogenase | KHF80729.1 | 49 | 1.2/0.9 | 0/0 | 0.012 |
| 13435 fda      | fructose-1,6-bisphosphate aldolase | KHF79653.1 | 33 | 1.2/0.9 | 0/0 | 0.012 |
| 12010 rpiA     | ribose 5-phosphate isomerase | KHF79390.1 | 26 | 1.2/0.9 | 0/0 | 0.012 |
| 05910\(^*\) codY | transcriptional repressor CodY | KHF80889.1 | 29 | 1.2/2.6 | 0/0 | 0.058 |

\(^a\)ORF numbers are based on strain UAMS-1. ORF numbers with an asterisk (*) indicate proteins with a P value of >0.05. ORF numbers that are underlined indicate proteins also found in acute secretome.

\(^b\)The ID number is the Uniprot accession number.

\(^c\)Two biological replicates were used to identify matrix proteins. The spectral counts were normalized based on total counts.

\(^d\)—a gene name has not yet been assigned.

https://doi.org/10.1371/journal.pone.0187981.t003
| ORF^* QV15_ | gene   | Identified Proteins                                      | ID^p     | Mass (kDa) | Normalized count (expt 1/2)c | P value  |
|-------------|--------|----------------------------------------------------------|----------|------------|-------------------------------|----------|
| 00825       | pflB   | formate acetyltransferase                                 | KHF79941.1 | 85         | 497.5/469.9 o/0              | <0.001   |
| 00485       | adhE   | acetaldehyde dehydrogenase                                | KHF79877.1 | 95         | 143.9/127.6 o/0              | 0.002    |
| 02495       | tuf    | elongation factor Tu                                       | KHF80244.1 | 43         | 94.5/99.1 o/0               | <0.001   |
| 07020       | tdcB   | threonine dehydratase                                     | KHF81097.1 | 37         | 93.4/84.4 o/0               | 0.001    |
| 05465       | otc    | ornithine carbamoyltransferase                            | KHF80801.1 | 38         | 70.3/85.4 o/0               | 0.005    |
| 02780       | adhA   | ethanol-active dehydrogenase/ acetaldehyde-active reductase| KHF80259.1 | 36         | 80.2/67.9 o/0               | 0.003    |
| 07025       | aldZ   | alanine dehydratase                                       | KHF81098.1 | 40         | 63.7/67.0 o/0               | <0.001   |
| 06145       | glpD   | glycerol-3-phosphate dehydrogenase                       | KHF80936.1 | 62         | 71.4/58.7 o/0               | 0.005    |
| 11040       | glmS   | glucosamine—fructose-6-phosphate aminotransferase        | KHF79213.1 | 66         | 67.0/53.2 o/0               | 0.006    |
| 08265       | thrS   | threonyl-IRNA synthase                                    | KHF81365.1 | 74         | 40.6/69.8 o/0               | 0.032    |
| 08415       | uspA   | universal stress protein UspA                             | KHF81365.1 | 18         | 63.7/44.1 o/0               | 0.016    |
| 05470       | arcC1  | carbamoyl kinase                                          | KHF80802.1 | 34         | 59.3/44.1 o/0               | 0.011    |
| 13410       | ldh2   | lactate dehydratase                                       | KHF79648.1 | 34         | 56.0/42.2 o/0               | 0.010    |
| 10955       | pyn    | thymidine phosphorylase                                   | KHF79197.1 | 46         | 42.8/45.9 o/0               | 0.001    |
| 02490       | fusA   | elongation factor G                                       | KHF80243.1 | 77         | 30.8/28.5 o/0               | 0.001    |
| 03870       | eno    | enolase                                                   | KHF80499.1 | 47         | 24.2/30.3 o/0               | 0.006    |
| 10785       | atpD   | ATP F0F1 synthase subunit beta                            | KHF79163.1 | 51         | 31.9/22.9 o/0               | 0.013    |
| 13435       | fda    | fructose-1,6-bisphosphate aldolase                        | KHF79653.1 | 33         | 25.3/23.9 o/0               | <0.001   |
| 07765       | dnaK   | molecular chaperone DnaK                                  | KHF81241.1 | 66         | 23.1/24.8 o/0               | 0.001    |
| 03850       | gap1   | glyceraldehyde-3-phosphate dehydrogenase                 | KHF80495.1 | 36         | 19.8/22.0 o/0               | 0.001    |
| 02920       | mntA   | manganese ABC transporter substrate-binding protein       | KHF80325.1 | 35         | 16.5/22.9 o/0               | 0.013    |
| 08350       | pyk    | pyruvate kinase                                           | KHF81352.1 | 63         | 19.8/18.4 o/0               | 0.001    |
| 05560       | ftsZ   | cell division protein FtsZ                                | KHF80819.1 | 41         | 16.5/17.4 o/0               | <0.001   |
| 13625       | arcA   | arginine deiminase                                        | KHF79690.1 | 47         | 13.2/19.3 o/0               | 0.017    |
| 10795       | atpA   | ATP F0F1 synthase subunit alpha                           | KHF79165.1 | 55         | 18.7/13.8 o/0               | 0.011    |
| 13440       | mcp2   | malate:quinone oxidoreductase                             | KHF79654.1 | 56         | 13.2/16.5 o/0               | 0.006    |
| 07205       | rpsA   | 30S ribosomal protein S1                                  | KHF81133.1 | 43         | 12.1/16.5 o/0               | 0.012    |
| 13610       | arcC2  | carbamate kinase                                          | KHF79687.1 | 34         | 13.2/12.9 o/0               | <0.001   |
| 01650       | ahpF   | NADH dehydrogenase (alkyl hydroperoxide reductase subunit F) | KHF80099.1 | 55         | 12.1/12.9 o/0               | <0.001   |
| 04360       | -d     | hypothetical protein (putative fumarylacetate hydratase) | KHF80592.1 | 33         | 13.2/10.1 o/0               | 0.009    |
| 01655*      | ahpC   | alkyl hydroperoxide reductase                             | KHF80100.1 | 21         | 5.5/16.5 o/0               | 0.092    |
| 06140*      | glpK   | glycerol kinase                                           | KHF80935.1 | 56         | 4.4/17.4 o/0                | 0.118    |
| 06520       | tkt    | transketolase                                             | KHF81003.1 | 72         | 9.9/11.0 o/0                | 0.001    |
| 05170       | pyc    | pyruvate carboxylase                                      | KHF80747.1 | 129        | 8.8/11.9 o/0                | 0.011    |
| 05910       | codY   | transcriptional repressor CodY                           | KHF80889.1 | 29         | 8.8/8.3 o/0                 | <0.001   |
| 00925       | ldh1   | lactate dehydratase                                       | KHF79960.1 | 35         | 9.9/6.4 o/0                 | 0.021    |
| 08465       | rpsD   | 30S ribosomal protein S4                                  | KHF81374.1 | 23         | 8.8/6.4 o/0                 | 0.012    |
| 01055       | -d     | nitric oxide reductase                                    | KHF81528.1 | 88         | 6.6/6.4 o/0                 | <0.001   |
| 08685       | pepV   | dipeptidase PepV                                         | KHF81415.1 | 53         | 5.5/7.3 o/0                 | 0.010    |
| 11185       | -d     | iron citrate ABC transporter substrate-binding protein   | KHF79234.1 | 37         | 5.5/7.3 o/0                 | 0.010    |
| 05070       | pdhB   | 2-oxoisovalerate dehydrogenase                            | KHF80727.1 | 35         | 4.4/8.3 o/0                 | 0.041    |
| 12355*      | narG   | nitrate reductase                                         | KHF79452.1 | 140        | 2.2/9.2 o/0                 | 0.122    |
| 01700       | guaB   | inosine-5-monophosphate dehydrogenase                     | KHF80108.1 | 53         | 4.4/6.4 o/0                 | 0.017    |
| 11535       | rplB   | 50S ribosomal protein L2                                  | KHF79299.1 | 30         | 5.5/4.6 o/0                 | 0.004    |
| 08830       | tal    | transaldolase                                             | KHF81444.1 | 26         | 3.3/6.4 o/0                 | 0.045    |

(Continued)
found during acute infection were also found in chronic infection in the secretome (ORFs underlined in Tables 1 and 3), while 15 of the 17 proteins found in acute infection were found in chronic infection in the surfactome (ORFs underlined in Tables 2 and 4). The 6 proteins shared between secretome and surfacome in acute phase were also found in both proteomes in the chronic phase. Additional similarities to the acute phase profiles were that PflB was the predominant protein in surfactome and Oct was the predominant in secretome although Idh2 was no longer dominant in chronic infection. The repeated identification of the same proteins in different fractions and in both acute and chronic infection phases indirectly validates our experimental approach for identifying biofilm matrix proteins from infected tissues.

Table 4. (Continued)

| ORF^a QV15_ | gene | Identified Proteins | ID^b | Mass (kDa) | Normalized count (expt 1/2)^c | P value | expt | control |
|-------------|------|---------------------|------|------------|-----------------------------|---------|------|---------|
| 10575       | rsbW  | serine/threonine protein kinase | KHF79124.1 | 18 | 4.4/4.6 | 0/0 | <0.001 |
| 00275       | sok   | myosin-cross-reactive antigen | KHF79836.1 | 68 | 4.4/4.6 | 0/0 | <0.001 |
| 13145       | cplL  | Clp protease ClpL | KHF79599.1 | 78 | 3.3/5.5 | 0/0 | 0.029 |
| 05920       | rpsB  | 30S ribosomal protein S2 | KHF80891.1 | 29 | 3.3/5.5 | 0/0 | 0.029 |
| 10830       | upp   | uracil phosphoribosyltransferase | KHF79172.1 | 23 | 3.3/5.5 | 0/0 | 0.029 |
| 05080       | pdhD  | dihydrolipoamide dehydrogenase | KHF80729.1 | 49 | 5.5/2.8 | 0/0 | 0.047 |
| 00435       | deoC1 | deoxyribose-phosphate aldolase | KHF79867.1 | 24 | 4.4/3.7 | 0/0 | 0.004 |
| 10805       | atpF  | ATP F0F1 synthase subunit B | KHF79167.1 | 20 | 4.4/3.7 | 0/0 | 0.004 |
| 01080       | - -d | SAM-dependent methyltransferase | KHF79888.1 | 28 | 3.3/4.6 | 0/0 | 0.013 |
| 08420       | ackA  | acetate kinase | KHF81366.1 | 44 | 3.3/4.6 | 0/0 | 0.013 |
| 10225       | lukA  | Leukocidin toxin subunit | KHF79059.1 | 41 | 3.3/4.6 | 0/0 | 0.013 |
| 12370*      | nasD  | nitrite reductase | KHF79455.1 | 89 | 1.1/6.4 | 0/0 | 0.147 |
| 08595       | - -d | hypothetical protein | KHF81397.1 | 18 | 4.4/2.8 | 0/0 | 0.024 |
| 00380       | mraA  | MarR family transcriptional regulator | KHF80406.1 | 17 | 3.3/3.7 | 0/0 | 0.001 |
| 04225*      | - -d | NADH dehydrogenase | KHF80565.1 | 44 | 2.2/4.6 | 0/0 | 0.053 |
| 09770       | ppaC  | inorganic pyrophosphatase | KHF78973.1 | 34 | 3.3/3.7 | 0/0 | 0.001 |
| 02355       | nupC  | nucleoside permease | KHF80217.1 | 44 | 2.2/4.6 | 0/0 | 0.053 |
| 02525       | ilvE  | branched-chain amino acid aminotransferase | KHF80250.1 | 40 | 3.3/2.8 | 0/0 | 0.004 |
| 12010       | rpiA  | ribose 5-phosphate isomerase | KHF79390.1 | 26 | 2.2/3.7 | 0/0 | 0.029 |
| 05335       | trxA  | thioredoxin | KHF80778.1 | 11 | 2.2/3.7 | 0/0 | 0.029 |
| 00310       | sirA  | iron ABC transporter substrate-binding protein | KHF79843.1 | 37 | 2.2/3.7 | 0/0 | 0.029 |
| 08390*      | - -d | universal stress protein | KHF81360.1 | 15 | 1.1/4.6 | 0/0 | 0.122 |
| 05990*      | infB  | translation initiation factor IF-2 | KHF80905.1 | 78 | 1.1/4.6 | 0/0 | 0.122 |
| 09660*      | gatB  | glutamyl-tRNA amidotransferase | KHF78951.1 | 54 | 1.1/3.7 | 0/0 | 0.102 |
| 10585*      | rsbU  | serine/threonine protein phosphatase | KHF79126.1 | 38 | 1.1/2.8 | 0/0 | 0.073 |
| 11465*      | rpsE  | 30S ribosomal protein S5 | KHF79285.1 | 18 | 1.1/2.8 | 0/0 | 0.073 |
| 11510*      | rpmS  | 50S ribosomal protein L29 | KHF79294.1 | 8 | 1.1/2.8 | 0/0 | 0.073 |

*ORF numbers are based on strain UAMS-1. ORF numbers with an asterisk (*) indicate proteins with a P value of >0.05. ORF numbers that are underlined indicate proteins also found in acute surfactome.
^aThe ID number is the Uniprot accession number.
^bTwo biological replicates were used to identify matrix proteins. The spectral counts were normalized based on total counts.
^c—a gene name has not yet been assigned.
Most significantly, bi-component leukocidins, LukAB and HlgAB, were found in the chronic secretome. The UAMS-1 genome encodes 5 leukocidin subunit genes, only the HlgC, which is a subunit of the leukocidin HlgBC, was not detected. However, the HlgC protein was detected by reducing the Mascot search stringency to 95% peptide threshold suggesting that it is likely present in the secretome as well. LukA subunit was also found in the SDS-extracted surfactome. Leukocidins are cytotoxins that target host immune cells [25]. The detection of the leukocidins in the biofilm matrix during chronic infection, but not during acute infection, suggests that these toxins may play a role against the host immune system at a later stage of implant bone infection. However, it is also likely that these toxins were also present during acute infection in a low quantity that were not detected by our methodology.

A few surface-associated or anchored proteins were found in the chronic infection. Ebh and IsdA, which were found in the acute phase of infection in the secretome and surfactome, respectively, were identified in the secretome during chronic infection. In addition, SasF, a cell wall-anchoring protein [26], and Atl, a bifunctional autolysin [27], were two other surface protein identified in the chronic secretome. In the chronic surfactome, we identified two surface proteins, Sok and SirA. Sok is a myosin cross reactive antigen that has been implicated in resistance to oxidative killing [28], whereas SirA is a receptor involved in the uptake of siderophore staphyloferrin B [29]. Except for Atl, none of these surface proteins have been previously shown to be involved in biofilm formation or maintenance. Atl has been shown to contribute to initial attachment phase of biofilm formation as well as by inducing cell lysis thereby promoting eDNA release [30, 31].

We noted several cytoplasmic proteins that are involved in virulence or stress response were identified (Tables 3 and 4). Four transcriptional regulatory proteins involved in virulence regulation were found in the chronic surfactome, which include CodY, MgrA, RsbW and RsbU, in which the latter two are involved in modulating the activity of the alternative sigma factor SigB. In addition to virulence regulation, these regulators have been shown to be responded to stress signals (reviewed in [32]). UspA and TrxA, as in the acute infection, were also found in both proteomes during chronic infection. In addition, AhpF and AhpC, which are subunits of alkylhydroperoxide reductase involved in detoxification of organic peroxides [33], were found in chronic surfactome. These proteins are potentially important for bacteria to survive in oxidative stress encountered during infection. Although the role of these cytoplasmic proteins in biofilm is unclear, their presence may indicate that they were upregulated, which may reflect bacterial adaptation during chronic infection.

**Ebh and SasF are present in biofilm matrix in an acute infection**

To validate that the proteins identified above are indeed present in the biofilm matrix during infection, we performed immunohistochemistry using antibodies against two surface proteins, Ebh and SasF. Ebh was identified in the secretome of both acute and chronic infections. In contrast, SasF was only identified in the chronic secretome. However, when peptide threshold was lowered to 95% we also found SasF in the acute secretome suggesting that SasF could also be present during acute infection. To detect these proteins, we used the rat post-arthroplasty joint infection model using short solid stainless wires essentially followed the mouse post-arthroplasty joint infection model as described by Bernthal et al [9]. Because the goal here was to demonstrate staphylococcal proteins on the surface of implants, we used small solid wires, instead of tubes, such that bacterial cells could be detected in bone thin section near the implant surfaces. At day 6 post infection, femurs with implant were harvested, fixed, decalcified and thin-sectioned longitudinally along the implant. The sections were subjected to
hematoxylin and eosin (H&E) stain, Gram stain and immunofluorescent stain with anti-Ebh\textsubscript{N} (N-terminal half) or anti-SasF. As shown in Fig 1A and 1B, staphylococci were easily identifiable in the bone tissue by Gram stain and the infected bone tissues were laden with inflammatory cells compared to the uninfected control. Both Ebh and SasF were expressed in the infected tissues whereas they were absent in the tissues infected with their isogenic mutant (Fig 1C). These results indicate that Ebh and SasF are expressed by staphylococci during an acute bone implant infection. However, the tissues infected with mutant strains had pathological changes similar to those infected with the wild type strain (Fig 1B). Since ebh and sasF deletion mutants were both capable of causing infection suggesting that lacking either one of them does not have apparent effect on bacterial survival in bone tissues. The detection of Ebh and SasF in the infected tissues suggests that Ebh and SasF are components of the biofilm matrix although our immunohistochemistry method did not provide high resolution to map whether they are surface-associated or secreted. The results also validate our proteomic approaches for identifying biofilm matrix proteins directly from infected host tissues. Furthermore, the results indicate that proteins detected at low spectral counts could not be simply regarded as false positives.

Host proteins associated with \textit{S. aureus} implants infection

We next identified host proteins that were induced or repressed by \textit{S. aureus} infection. To this end, we compared host protein profiles with and without infection. We found 254 and 397 proteins had at least 2-fold difference with p-value of less than 0.05 in acute and chronic secretome profiles, respectively (S1 and S3 Tables). In the surfactome, 198 and 433 proteins were identified in acute and chronic samples, respectively (S2 and S4 Tables). The differentially expressed genes were also analyzed by using DAVID software (S5 Table). Most of these proteins were induced by \textit{S. aureus} infection. Proteins in various functional categories were identified but most belong to the category of immune response, cytoskeleton organization, cell
differentiation, metabolism, signal transduction and transport. The large number of differentially expressed host proteins identified in this study suggests that *S. aureus* infection results in a profound change in host protein production. This is not surprising as the host is expected to mount a strong defense response in an effort to clear *S. aureus* but the bacterial persist in biofilm. While some of these proteins are not known to play a role in bacterial infection, some are known. For example, peptidoglycan recognition protein 1, which has amidase activity and binds to peptidoglycan in response to bacterial infection [34, 35], was highly induced (at least 3.8-fold) in all four profiles (although the p value in acute secretome is 0.064). Lipopolysaccharide binding protein, (LBP), which have been shown to interact with lipoteichoic acid of *S. aureus* [36], were also detected in both chronic samples. LBP has also been shown to be induced by *S. aureus* in an experimental intramammary infection during clinical mastitis [37]. As bacterial cell wall components are important immunogens recognized by host receptors, these results further indirectly validate our results. While the majority of the proteins were induced by *S. aureus* infection, we found some proteins were suppressed. Of these, the most noticeable were collagen components and related proteins involved in collagen formation, particularly in chronic infection samples. Concomitantly, collagen degradation enzymes were found to be significantly increased. Taken together, these results suggest that *S. aureus* infection in bone results in reduction in collagen, a main component in bone, by inducing host enzymes that degrade collagen. However, it is possible that production of staphylococcal proteases could also play a role.

**Discussion**

The composition of matrix protein of biofilms formed during an *S. aureus* infection has not been reported. Limited biofilm materials that could be recovered from infected tissues, heavy contamination with host proteins, and availability of sensitive proteomic analytical methods are likely the limiting factors for assessing biofilm matrix composition directly from biofilms obtained from an in vivo infection. In this study, we attempted to identify proteins from biofilms formed on bone implants during acute and chronic phases of infection in rats by using GeLC-MS/MS. To obtain sufficient biofilm materials for analyses, we used large rats to accommodate implants that are too large for mice. By using this strategy, we were able to obtain enough biofilm materials for bacterial protein identification from implants harvested during acute infection as well as chronic infection. Despite the vast majority of the proteins identified were rat proteins, we were able to identify many bacterial proteins. In the negative control experiments without an infection, we identified only rat proteins without *S. aureus* proteins. Thus, we are confident that most, if not all, bacterial proteins that we identified in this study were of *S. aureus* and not false positives due to heavy contamination of rat proteins. Furthermore, we have used immunofluorescent staining against Ebh and SasF to verify that *S. aureus* proteins were indeed expressed in the rat bone tissue surrounding the infected implants. However, because of the heavy presence of host proteins, it is very likely that *S. aureus* proteins presence in a small amount were not identified. This limitation is difficult to avoid with the current technology. Thus, our results are likely to underestimate the number of staphylococcal proteins present in the matrix. This could also explain that SasF was positively identified in the immunofluorescent stain but was only identified in the acute infection when less stringent Mascot search criteria were used.

In *S. aureus*, polysaccharides, eDNA and proteins have been found in biofilm matrix under in vitro conditions but the components vary depending on the environment that the organism resides [38]. In this work, we used sonication and SDS to release proteins from the matrix of staphylococcal biofilm formed on metal implants. Sonication has been shown to be an effective
method of removing biomatrix materials from biofilm [39], whereas SDS is an effective agent to extract surface-associated proteins without lysing staphylococci [12, 13]. We therefore assume that sonication should be able to release most proteins secreted/released into the extracellular biofilm matrix and the subsequent SDS treatment should release those that adhere or non-covalently associate with the bacterial surfaces. We found more proteins in the SDS fraction than the sonication fraction suggesting that many proteins are secreted/released but associated with the cell surface. We also found that the number of bacterial proteins identified in the chronic phase was much more than that in the acute phase suggesting that S. aureus continues to secrete diverse proteins once it establishes a long-termed chronic infection. This transition in protein profile suggests that S. aureus is actively modulating its environment during the course of the infection. Most significantly, leukocidins (LukAB, HlgAB and likely HlgCB) were identified in the biofilm matrix during chronic infection although UAMS-1 is capable of producing many other extracellular toxins and virulence factors with a notable exception of alpha-toxin due to a nonsense mutation [40]. Leukotoxins have been shown to target neutrophils, macrophages and monocytes [25]. In addition, HlgAB has also been shown to lyse erythrocytes, which are abundant in bone marrow, to release hemoglobin for iron source [41]. The presence of leukocidins in the biofilm matrix suggests that they play a pivotal role in bacterial survival and persistence in biofilm during bone infection by damaging host immune cells. Lysis of host immune cells would also trigger inflammatory response that could further cause tissue damage [25]. Our results further indicate that S. aureus not only protects itself by physically shielding from host immune system within the biofilm matrix but also actively releasing toxins to attack the host defense system. This is consistent with a recent study showing that LukAB as well as alpha-toxin actively produced from S. aureus USA300 LAC biofilms cause macrophage dysfunction in a murine model of orthopedic implant biofilm infection [42]. Leukotoxins and alpha-toxin have also been detected in biofilm using a human epidermal model [43].

The majority of the bacterial proteins we identified are cytoplasmic proteins. Cytoplasmic proteins have been found to be secreted extracellularly in many bacteria, including S. aureus [23, 44–46]. Our results are consistent with studies showing that many cytoplasmic proteins are found in the matrix of S. aureus biofilm formed in vitro [8, 24, 47]. In particular, Foulston et al. [24] show that most proteins found in the matrix from in vitro static S. aureus biofilms are cytoplasmic proteins. Thus, cytoplasmic proteins are likely the major matrix components of in vitro as well as in vivo biofilms. Bacterial programmed cell death during biofilm formation has been shown to release DNA that contributes to biofilm matrix formation [5]. This regulated autolysis is likely to result in release of intracellular proteins. However, studies have shown that cell lysis cannot explain the extracellular accumulation of cytoplasmic proteins but the molecular mechanisms involving in such secretion are still unknown [48, 49]. It has been reported that some of the released cytoplasmic proteins function as adhesins that interact with host cells [23]. However, as we found that many of these cytoplasmic proteins were only found in mature biofilm matrix during chronic infection, it is unlikely that they serve as adhesins for initial biofilm formation. Thus, other than moonlighting as components of biofilm matrix, whether these cytoplasmic proteins play additional roles awaits further investigation.

We found a total of 5 surface proteins (Ebh, SasF, Atl, IsdA and Sok) in this study of which Ebh and SasF were shown to be in the biofilm matrix using immunohistochemistry. However, both ebh and sasF mutants showed similar pathological changes as the wild type suggesting that they are not essential for implant biofilm formation although we did not measure the bacterial load on the implants. More than a dozen of S. aureus surface proteins have been demonstrated to be involved in biofilm formation in vitro [6, 7]. Strain UAMS-1 possesses eight of
these proteins in the genome, which include FnbA, ClfA, ClfB, SdrC, SasC, Spa, Atl and SraP [14] but only Atl was identified in our study. Whether the other four surface proteins we identified play a role in biofilm formation/maintenance remained to be studied.

Although the main goal of this study is to identify bacterial proteins during infection, the proteomic approach also allowed us to identify host proteins that are affected by *S. aureus* infection. By analyzing host proteins differentially expressed globally, we provided a snapshot of host proteomic changes upon bone implant infection at both acute and chronic phases. We found profound changes in host proteins upon infection. This is not surprising because host is expected to mount a strong immune defense system to eliminate the invader in response to bacterial infection. However, although many proteins related to immune responses are to be expected, we found many more proteins that have not been implicated in response to *S. aureus* infections. It should be noted that our method in which sonication and 4% SDS were used to release bacterial proteins may also cause lysis of host cells. Thus, the host proteins shown in S1 to S4 Tables may also contain released proteins due to cell lysis. Nevertheless, our results provide a useful information for further in-depth studies on host-bacteria interaction during biofilm-related *S. aureus* infection.

**Materials and methods**

**Ethics statement**

All animal experiments were approved by the Institutional Animal Care and Use committee (IACUC) at the University of Arkansas for Medical Sciences.

**Bacteria**

*S. aureus* UAMS-1 [11] and its derivatives were grown routinely in tryptic soy medium. *E. coli* XL-Blue, used for cloning purpose, was grown in Luria-Bertani medium. Antibiotics were added to the culture medium when necessary, at final concentrations of 10 μg/ml for erythromycin and chloramphenicol and 100 μg/ml for ampicillin. The primers used in this study are listed in S6 Table. To construct UAMS-1 Δebh::ermC mutant (CYLA25) and ΔsasF::ermC mutant (CYLA23), deletions were made by overlapping PCR using primer sets ebh1-4 and sasF1-4 (S6 Table), respectively. Each of the resulting fragment contains a NotI sequence in place of the deleted sequence. The amplified fragments were verified by sequencing and cloned into pJB38 to which a NotI fragment containing the *ermC* gene amplified by primer pairs erm11 and erm12 (S6 Table) from pCN44 [50] and cloned in pGEMT-easy (Promega, Madison WI) was inserted. Mutants were obtained by allele replacement as described previously [51]. The mutations were confirmed by PCR.

**Rats and infection model**

*Rat orthopedic implant-associated infection model.* Sprague-Dawley (Harlan Inc., Indianapolis, IN) male adult rats of 420–520 g were anesthetized via inhalation of isoflurane (2%). Buprenex (15 μg) was injected subcutaneously and dispersed by gentle rubbing. A skin incision was made over the right knee to access the distal femur through a medical parapatellar arthrotomy with lateral displacement of the quadriceps-patellar complex. The femoral intramedullary canal was reamed with an 18-gauge (18G) needle and further opened with a handheld drill (size 13G drill bit). One piece of 1-cm long orthopaedic-grade hypodermic stainless steel tubing (size 15G; Vita Needle Co., Needham, MA) that had been soaked with $1 \times 10^4$ CFU/ml of *S. aureus* UAMS-1 or with PBS (control) was surgically placed into the femur. A total of
50 CFUs in 5 μl PBS or PBS alone was then inoculated in the lumen of the implant before the quadriceps-patellar complex was reduced to midline and the surgical site closed by sutures. Rats were sacrificed at 6 or 45 days after infection, representing acute and chronic infection, respectively. Implants were removed to collect biofilm and bacteria for matrix proteins and cell surface-associated proteins isolation.

**Rat post-arthroplasty joint infection model.** Sprague-Dawley male rats weighing 250–300 g were used in this model essentially as described by Bernthal et al. [9] in their mouse post-arthroplasty joint infection model. A 2-cm hypodermic stainless steel rod (size 23G; Vita Needle Co.) presoaked with 1x10⁴ CFU/ml *S. aureus* UAMS-1, Δebh or Δasf mutant was inserted into the medullary cavity with 1 mm protruding out. The protruding ends were infected with 2 μl of bacterial suspension (20 CFUs) in PBS before the quadriceps-patella complex was returned to midline and the surgery site closed with suture.

**Protein isolation and identification**

The implants were removed, rinsed in 1 ml sterile saline and transferred to a 5ml-culture tube containing 1 ml sterile saline with protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). The materials in the tubing were then dislodged with a wire and subjected to sonication in a Misonix Sonicator 3000 (Thermo Fisher Scientific, Waltham, MA) using micro-tip with four 10-s pulse at full power and 30-s intervals in between on ice. The mixtures were centrifuged at 6,000xg. The supernatants, representing exoprotein proteome fraction (secretome), were TCA precipitated and resuspended in SDS sample buffer. The pellets were resuspended in 4% SDS (10 μl per implant), incubated at room temperature for 1 h, centrifuged at 18,000xg, and the supernatants were defined as the surface proteome fraction (surfactome). The proteins in each fraction were analyzed in 4–15% gradient SDS-PAGE (Bio-Rad) and stained with Coomassie Blue G250, the gel lanes were equally cut into 3 mm slices and subjected to in-gel trypsin digestion as follows. Gel slices were destained in 50% methanol (Thermo Fisher), 100 mM ammonium bicarbonate (Sigma, St Louis, MO), followed by reduction in 10 mM Tris(2-carboxyethyl)phosphine (Pierce, Rockford, IL) and alkylation in 50 mM iodoacetamide (Sigma). Gel slices were then dehydrated in acetonitrile (Thermo Fisher), followed by addition of 100 ng porcine sequencing grade modified trypsin (Promega) in 100 mM ammonium bicarbonate (Sigma) and incubation at 37°C for 12–16 hours. Peptide products were then acidified in 0.1% formic acid (Pierce). Trypsin peptides were separated by reverse phase Jupiter Proteo resin (Phenomenex, Torrance, CA) on a 200 x 0.075 mm column using a nanoAcquity UPLC system (Waters, Milford, MA). Peptides were eluted using a 30 min gradient from 97:3 to 65:35 buffer A:B ratio (Buffer A = 0.1% formic acid, 0.5% acetonitrile; buffer B = 0.1% formic acid, 99.9% acetonitrile). Eluted peptides were ionized by electrospray (2.15 kV) followed by MS/MS analysis using higher-energy collisional dissociation (HCD) on an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher) in top-speed data-dependent mode. MS data were acquired using the FTMS analyzer in profile mode at a resolution of 240,000 over a range of 375 to 1500 m/z. Following HCD activation, MS/MS data were acquired using the ion trap analyzer in centroid mode and normal mass range with precursor mass-dependent normalized collision energy between 28.0 and 31.0. Proteins were identified by database search using Mascot (Matrix Science, London, UK) with a parent ion tolerance of 3 ppm and a fragment ion tolerance of 0.5 Da. Scaffold (Proteome Software, Portland, OR) was used to verify MS/MS based peptide and protein identifications. Protein probabilities were assigned by the Protein Prophet algorithm [52]. Functional enrichment analysis of the host proteins was carried out using DAVID (https://david.ncifcrf.gov/) software program [53].
Histology and immunohistochemistry analysis

At day 6 post-infection, whole femurs with implant were harvested, fixed in 10% formalin for 3 d, rinsed 3 times with Milli-Q water, and decalcified in Super Decalcifier I solution (Polysciences, Warrington, PA). The decalcified femurs were sent to Nationwide Histology (Vera-dale, WA) for paraffin embedding, mounting, thin-sectioning (4 μm thick, longitudinal to the implant), and routine hematoxylin-eosin (H&E) and Gram staining. To detect Ebh and SasF in infected tissues, the procedure for immunohistochemistry analysis was essentially as described by Cheng et al. [16]. Briefly, sections on microscope slides were treated with xylene (5 min, 3 times), followed by 100% ethanol (10 min, 2 times) then by 95, 70 and 50% ethanol for 5 min each. After rinsing with deionized water, the samples were rehydrated with PBS for 10 min and immersed in Uni-Trieve solution (Innovex Biosciences, Richmond, CA) for antigen retrieval for 30 min. The slides were blocked in human IgG (Sigma), followed by primary specific rabbit antibody (1:5000) of anti-Ebh [16] or anti-SasF [26] and AlexaFluor-647 conjugated goat-anti-rabbit secondary antibody (1:10,000; Invitrogen, Waltham, MA) for 1 h each in 3% BSA, 0.1% Tween 80 in 1x PBS and rinsed 3 times with 1x PBS in between. To reduce the background, primary antibodies were pre-absorbed with respective mutant strains. Finally, the slides were placed in 1x PBS containing 10 μg/ml Hoechst dye (Invitrogen) and 1 μg/ml BODIPY-vancomycin (Invitrogen) for 5 min. The slides were washed with PBS and mounted in N-propylgallate (Sigma) and viewed under a laser confocal microscope (Nikon Eclipse Ti, Nikon Instruments Inc., Melville, NY).

Supporting information

S1 Table. Host proteins by sonication affected by *S. aureus* during acute phase of infection. (XLS)

S2 Table. Host proteins by SDS-extraction affected by *S. aureus* during acute phase of infection. (XLS)

S3 Table. Host proteins by sonication affected by *S. aureus* during chronic phase of infection. (XLS)

S4 Table. Host proteins by SDS-extraction affected by *S. aureus* during chronic phase of infection. (XLS)

S5 Table. Functional enrichment analysis of host proteins affected by *S. aureus* during infection. (DOCX)

S6 Table. Oligonucleotide primers used in this study. (DOCX)

Acknowledgments

We thank Olaf Schneewind and Simon Foster for anti-Ebh antisera and Timothy Foster for anti-SasF antisera. We thank Tammy Kielian for help with preparing bone tissues for thin sections. We thank UAMS core facilities, which are supported in part by National Institutes of Health grants S10OD018445 and P20GM103625. This work is supported by grant AI112028 from the National Institute of Allergy and Infectious Diseases.
Author Contributions

Conceptualization: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.
Data curation: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.
Formal analysis: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.
Funding acquisition: Mei G. Lei, Chia Y. Lee.
Investigation: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.
Methodology: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.
Project administration: Chia Y. Lee.
Resources: Chia Y. Lee.
Supervision: Chia Y. Lee.
Validation: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.
Visualization: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.
Writing – original draft: Mei G. Lei, Ravi Kr. Gupta.
Writing – review & editing: Mei G. Lei, Ravi Kr. Gupta, Chia Y. Lee.

References

1. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Ann Rev Microbiol. 1995; 49: 711–745.
2. Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol. 2008; 322: 207–228. PMID: 18453278
3. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000; 54: 49–79. https://doi.org/10.1146/annurev.micro.54.1.49 PMID: 11018124
4. Götz F. Staphylococcus and biofilms. Mol Microbiol. 2002; 43: 1367–1378. PMID: 11952892
5. Bayles KW. The biological role of death and lysis in biofilm development. Nat Rev Microbiol. 2007; 5: 721–726. https://doi.org/10.1038/nrmicro1743 PMID: 17694072
6. Paharik AE, Horwill AR. The staphylococcal biofilm: adhesins, regulation, and host response. Microbiol spectr. 2016; 4(2).
7. Speziale P, Pietrocola G, Foster TJ, Geoghegan JA. Protein-based biofilm matrices in staphylococci. Front Cell Infect Microbiol. 2014; 4: 171. https://doi.org/10.3389/fcimb.2014.00171 PMID: 25540773
8. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect Immun. 2006; 74: 3415–3426. https://doi.org/10.1128/IAI.00392-06 PMID: 16714572
9. Bernthal NM, Stavrakis AI, Billi F, Cho JS, Kremen TJ, Simon SI, et al. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PloS one. 2010; 5: e12580. https://doi.org/10.1371/journal.pone.0012580 PMID: 20830204
10. Pribaz JR, Bernthal NM, Billi F, Cho JS, Ramos RI, Guo Y, et al. Mouse model of chronic post-arthroplasty infection: Noninvasive in vivo bioluminescence imaging to monitor bacterial burden for long-term study. J Orthop Res. 2012; 30: 335–340. https://doi.org/10.1002/jor.21519 PMID: 21837886
11. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect Immun. 1995; 63: 3373–3380. PMID: 7642265
12. Sugai M, Akiyama T, Komatsuzawa H, Miyake Y, Suginaka H. Characterization of sodium dodecyl sulfate-stable Staphylococcus aureus bacteriolitic enzymes by polyacrylamide gel electrophoresis. J Bacteriol. 1990; 172: 6494–6498. PMID: 2229971
13. Schneewind O, Model P, Fischetti VA. Sorting of protein A to the staphylococcal cell wall. Cell. 1992; 70: 267–281. PMID: 1636631
14. Sassi M, Sharma D, Brinsmade SR, Felden B, Augagneur Y. Genome sequence of the clinical isolate Staphylococcus aureus subsp. aureus strain UAMS-1. Genome Announc. 2015; 3: e01584–14. https://doi.org/10.1128/genomeA.01584-14 PMID: 25676774
15. Clarke SR, Harris LG, Richards RG, Foster SJ. Analysis of Ebh, a 1.1-megadalton cell wall-associated fibronecrtin-binding protein of Staphylococcus aureus. Infect Immun. 2002; 70: 6680–6687. https://doi.org/10.1128/IAI.70.12.6680-6687.2002 PMID: 12438342

16. Cheng AG, Missiakas D, Schneewind O. The giant protein Ebh is a determinant of Staphylococcus aureus cell size and complement resistance. J Bacteriol. 2014; 196: 971–981. https://doi.org/10.1128/JB.01366-13 PMID: 24363342

17. Mazmanian SK, Skaar EP, Gaspar AH, Humayun M, Gornicki P, Jelenska J, et al. Passage of heme-iron across the envelope of Staphylococcus aureus. Science. 2003; 299: 906–909. https://doi.org/10.1126/science.1081147 PMID: 12574635

18. Uziel O, Borovok I, Schreiber R, Cohen G, Aharonowitz Y. Transcriptional regulation of the Staphylococcus aureus thioredoxin and thioredoxin reductase genes in response to oxygen and disulfide stress. J Bacteriol. 2004; 186: 326–334. https://doi.org/10.1128/JB.186.2.326-334.2004 PMID: 14702300

19. Nyström T, Neidhardt FC. Expression and role of the universal stress protein, UspA, of Escherichia coli during growth arrest. Mol Microbiol. 1994; 11: 537–544. PMID: 8152377

20. Kvint K, Nachin L, Diez A, Nyström T. The bacterial universal stress protein: function and regulation. Curr Opin Microbiol. 2003; 6: 140–145. PMID: 12732303

21. Liu WT, Karavolos MH, Bulmer DM, Alloupi A, Romaeche RD, Lee JJ, et al. Role of the universal stress protein UspA of Salmonella in growth arrest, stress and virulence. Microbial pathogenesis. 2007; 42: 2–10. https://doi.org/10.1016/j.micpath.2006.09.002 PMID: 17081727

22. Henderson B, Martin A. Bacterial virulence in the moonlight: multitasking bacterial moonlighting proteins are virulence determinants in infectious disease. Infect Immun. 2011; 79: 3476–3491. https://doi.org/10.1128/IAI.00179-11 PMID: 2164455

23. Wang W, Jeffery CJ. An analysis of surface proteomics results reveals novel candidates for intracellular/surface moonlighting proteins in bacteria. Mol Biosyst. 2016; 12: 1420–1431. https://doi.org/10.1039/c5mb00550g PMID: 26938107

24. Foulston L, Elsholz AK, DeFrancesco AS, Losick R. The extracellular matrix of Staphylococcus aureus biofilms comprises cytoplasmic proteins that associate with the cell surface in response to decreasing pH. mBio. 2014; 5: e01667-14. https://doi.org/10.1128/mBio.01667-14 PMID: 25182325

25. Alonzo F, Torres VJ. The bicompone nt pore-formin g leucocidin s of Staphylococcus aureus. Microbiol Mol Biol Rev. 2014; 78: 662–682. https://doi.org/10.1128/MMBR.00055-13 PMID: 24847020

26. Fournier B, Philpott DJ. Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev. 2005; 18: 521–540. https://doi.org/10.1128/CMR.18.3.521-540.2005 PMID: 16020688
involved. J Biol Chem. 2003; 278: 15587–15594. https://doi.org/10.1074/jbc.M212829200 PMID: 12594207

37. Bannerman DD, Paape MJ, Lee JW, Zhao X, Hope JC, Rainard P. *Escherichia coli* and *Staphylococcus aureus* elicit differential innate immune responses following intramammary infection. Clin Diagn Lab Immunol. 2004; 11: 463–472. https://doi.org/10.1128/CDLI.11.3.463-472.2004 PMID: 15138171

38. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010; 8: 623–633. https://doi.org/10.1038/nmico2415 PMID: 20676145

39. Zamowski R, Sanchez H, Andes DR. Large-scale production and isolation of Candida biofilm extracellular matrix. Nat Protoc. 2016; 11: 2320–2327. https://doi.org/10.1038/nprot.2016.132 PMID: 27809313

40. Cassat JE, Dunnam PM, McAleese F, Murphy E, Projan SJ, Smeltzer MS. Comparative genomics of *Staphylococcus aureus* musculoskeletal isolates. J Bacteriol. 2005; 187: 576–592. https://doi.org/10.1128/JB.187.2.576-592.2005 PMID: 15629929

41. Enany S, Yoshida Y, Magdeldin S, Bo X, Zhang Y, Enany M, et al. Two dimension electrophoresis of the exo-proteome produced from community acquired methicillin resistant *Staphylococcus aureus* belonging to clonal complex 80. Microbiol Res. 2013; 168: 504–511. https://doi.org/10.1016/j.micres.2013.03.004 PMID: 23566758

42. Gil C, Solano C, Burgui S, Latasa C, García B, Toledo-Arana A, et al. Biofilm matrix exoproteins induce a protective immune response against *Staphylococcus aureus* biofilm infection. Infect Immun. 2014; 82: 1017–1029. https://doi.org/10.1128/IAI.00617-08 PMID: 19364833

43. Muthukrishnan G, Quinn GA, Lamers RP, Diaz C, Cole AL, Chen S, et al. Exoproteome of *Staphylococcus aureus* reveals putative determinants of nasal carriage. J Proteome Res. 2010; 10: 2064–2078. https://doi.org/10.1021/pr100029r PMID: 21338050

44. Pasztor L, Ziebandt AK, Nega M, Schlag M, Haase S, Franz-Wachtel M, et al. Staphylococcal major autolysin (Atl) is involved in excretion of cytoplasmic proteins. J Biol Chem. 2010; 285: 36794–36803. https://doi.org/10.1074/jbc.M110.167312 PMID: 20847047

45. Nesižvíski AI, Keller A, Kolker E, Aebi R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003; 75: 4646–4658. PMID: 14632076

46. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 2009; 4: 44–57.